<DOC>
	<DOCNO>NCT02094417</DOCNO>
	<brief_summary>The present study conduct evaluate efficacy safety AMG531 determine recommend initial dose AMG531 basis efficacy safety administer subcutaneously ( SC ) Aplastic Anemia ( AA ) patient immunosuppressive-therapy refractory thrombocytopenia also assess pharmacokinetics product . Its efficacy safety extension period beyond one year also evaluate .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety AMG531 Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Patient diagnose AA refractory immunosuppressive therapy Platelet ≤ 30,000/μL Concurrent active infection adequately respond appropriate therapy HIV positivity Bone marrow reticulin grade &gt; 1 Clinically significant cardiac disease Arterial venous thrombosis within last 1 year enrollment Other cause thrombocytopenia AA hemolytic predominant paroxysmal nocturnal hemoglobinuria ( PNH ) Uncontrolled diabetes Receiving agent use treat AA , include antithymocyte globulin ( ATG ) ATG + cyclosporine within 6 month start study treatment and/or cyclosporine anabolic hormone within 6 week start study treatment History PEGrHuMGDF , recombinant human thrombopoietin , AMG531 , thrombopoietin ( TPO ) receptor agonist Who plan conduct hematopoietic stem cell transplantation within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anemia , Aplastic</keyword>
	<keyword>Thrombopoietin</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>